Medidata, a Dassault Systèmes company, has announced the launch of the Medidata Decentralized Clinical Trials (DCT) Program, a comprehensive set of unified, secure technologies that enable full decentralization across the clinical trial continuum. Drug, vaccine, and medical device developers (sponsors) and contract research organizations (CROs) can take advantage of the platform offering on the market which combines:
Technology and workflows to virtualize patient participation
Tools that facilitate sponsor oversight of patient safety and data quality
Direct-to-patient services, including facilitation of delivery of study drugs to the home
To date, Medidata has applied its decentralizing technologies across more than 44,000 clinical sites around the world in multiple languages involving more than 600,000 patients with a wide array of illnesses.
